Impact of immunosuppression on the immune response to SARS-CoV-2 infection: A mechanistic study.
Transpl Infect Dis
; 23(6): e13743, 2021 Dec.
Article
in English
| MEDLINE | ID: covidwho-1476358
ABSTRACT
The optimal management of immunosuppression in transplant patients infected with COVID-19 is unknown. We performed an in vitro study to determine the effect of individual immunosuppressive agents on SARS-CoV-2-specific T-cell cytokine expression. Convalescent peripheral blood mononuclear cells from eleven non-immunosuppressed patients with COVID-19 were preincubated with clinically relevant concentrations of immunosuppressive drugs (tacrolimus, mycophenolate, sirolimus, prednisone) and then stimulated with a SARS-CoV-2 peptide pool. Supernatants were analyzed by 14-plex high sensitivity T-cell cytokine array. With increasing concentrations of tacrolimus, there was a trend to reduction in the release of IL-2 (p = .0137), and IFN-γ (p = .0147) in response to peptide stimulation. There was also a subsequent trend toward a Th2 phenotype, indicated by lower IFN-γIL-13 ratio (p = .0663) and IFNγIL-4 ratio (p = .0176). Sirolimus appeared to be associated with a proinflammatory cytokine release, including TNF-α (p = .0027) and IL-1ß (p = .0016), in response to SARS-CoV-2 peptides. In contrast, mycophenolate and prednisone did not influence the SARS-CoV-2-specific cytokine response. These are preliminary findings only, with larger studies required to inform clinical recommendations.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Cytokines
/
Immunosuppression Therapy
/
COVID-19
Type of study:
Experimental Studies
/
Prognostic study
Limits:
Humans
Language:
English
Journal:
Transpl Infect Dis
Journal subject:
Transplantation
Year:
2021
Document Type:
Article
Affiliation country:
Tid.13743
Similar
MEDLINE
...
LILACS
LIS